The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk (ARMOPREVCVR)
|ClinicalTrials.gov Identifier: NCT01293162|
Recruitment Status : Completed
First Posted : February 10, 2011
Last Update Posted : February 3, 2016
Cardiovascular risk has been shown to increase with increasing blood pressure values. As a consequence, it results mandatory to achieve lower blood pressure goals in all hypertensive patients, taking into account that all drugs always have some side effects that can be very dangerous and/or uncomfortable for the patients leading to a reduced compliance. Thus, pharmacological treatment should be delayed until it results really necessary.
The availability of natural substances with a therapeutic action has modified this scenario because of their reduced potential to cause undesirable effects (compared with drugs). In order to choose among various nutraceuticals (natural foods compounds with health benefits, including the prevention and/or treatment of diseases), preference should be given to those
- produced according to the same Good Manufacturing Practice used for drugs, to be sure that the finished product has a standard, reproducible composition
- for which efficacy and safety in the recommended indications are supported by clinical trials.
An example of a product with these characteristics is Armolipid Plus, a combination of nutraceuticals with a demonstrated anti-dyslipidaemic effect. Recently, a large clinical intervention study showed evidence that treatment with Armolipid Plus leads to a significant decrease in the overall cardiovascular risk, measured using the Framingham Risk Score.
Progress in Research and Development in this field has led to a new patented and registered combination of nutraceuticals: Armolipid Prev, containing orthosiphon and CoQ10, with antihypertensive activity, berberine, red yeast, policosanol and orthosiphon with antidyslipidaemic effect and folic acid, reducing plasma homocysteine levels.
In addition to the established anti-dyslipidaemic activity of Armolipid plus, Armolipid Prev has a significant antihypertensive effect, which is beneficial in all those patients with high blood pressure values without a defined indication to begin a pharmacological treatment according to the current guidelines. The antihypertensive effect of Armolipid Prev, documented by ambulatory blood pressure monitoring, in addition to the lowering effect on dyslipidaemia and even on abdominal girth, represents a new opportunity for complete and early, effective and safe cardiovascular disease prevention.
|Condition or disease||Intervention/treatment||Phase|
|Metabolic Syndrome||Drug: Armolipid Prev||Phase 4|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||150 participants|
|Observational Model:||Case Control|
|Official Title:||Study on the Role of a Combination of Nutraceuticals (Armolipid Prev) With an Effect on Blood Pressure and Lipids in the Control of Cardiovascular Risk|
|Study Start Date :||September 2010|
|Primary Completion Date :||October 2014|
|Study Completion Date :||October 2014|
Drug: Armolipid Prev
Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
- Cardiovascular risk [ Time Frame: 12 months ]
Reduction the global cardiovascular risk calculated according to Framingham risk score compared to baseline.
Reduction of incident metabolic syndrome defined according to ATPIII criteria compared to baseline.
Reduction of the prevalence of microalbuminuria evaluated by standard methods compared to baseline.
Reduction of the prevalence of left ventricular hypertrophy evaluated by the ECG using the current ECG criteria (the Sokolow-Lyon index) compared to baseline.
- Life style [ Time Frame: 12 months ]Increasing compliance with a healthy lifestyle assessed by office interview of the patients at baseline and at the end of follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01293162
|Ambulatorio Ipertensione e Unità Coronarica Federico II University|
|Napoli, Italy, 80131|
|Study Director:||Bruno Trimarco, MD||Federico II University, Dipartimento di medicina Clinica Scienze Cardiovascoalri ed Immunologiche|